FDC Limited (NSE: FDC) today announced its unaudited consolidated financial results for the second quarter and half-year ended September 30, 2026, showcasing robust growth across segments. The company’s revenue from operations for Q2 FY27 stood at Rs. 572 crores, a year-on-year increase of 21.0% over Rs. 473 crores in Q2 FY26. Domestic Formulations grew 22.6% Y-o-Y, led by Electral and Enerzal, while International Formulations grew 28.5% Y-o-Y in Q2 and 47.6% in H1 FY27.

Domestic Formulations Lead Growth

Domestic Formulations returned to double-digit growth in Q2 FY27, with revenue of Rs. 467 crores, up 22.6% Y-o-Y from Rs. 381 crores in Q2 FY26. The recovery was driven by flagship brands Electral and Enerzal, and Zifi, which overcame earlier quarter challenges.

International Formulations Continue Momentum

International Formulations continued their growth trajectory in Q2 FY27, with sales of Rs. 75 crores, up 28.5% Y-o-Y from Rs. 58 crores in Q2 FY26. For H1 FY27, International Formulations sales rose 47.6% Y-o-Y to Rs. 148 crores, from Rs. 101 crores in H1 FY26.

API Segment Sees Decline

The API business recorded sales of Rs. 28 crores in Q2 FY27, against Rs. 30 crores in Q2 FY26 (-4.8% Y-o-Y). For H1 FY27, API sales declined 4.0% Y-o-Y to Rs. 52 crores, from Rs. 54 crores in H1 FY26, mainly due to lower sales of one key molecule.

As a result, FDC Limited (NSE: FDC) is poised for continued growth, with a strong foundation in both domestic and international markets. The company remains committed to exploring innovative solutions and expanding its healthcare horizons globally.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of FDC Limited

FDC Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

FDC falls 15.2% over three months and has not found a floor yet. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 1.50 sits close to fair value. The stock is neither a clear buy nor obviously expensive. Buyers show up with 1.4x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 6.8% and profits at 13.2%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.50 premium is usually justified. Check Fundamentals of FDC Limited.

Medplus Health Services Limited (MEDPLUS) has announced its Q2 FY2027 results, showcasing a robust performance in the quarter. The company reported a revenue of ₹20,371 million, marking a significant 21.3% year-over-year increase. The gross margin stood at 25.1%, reflecting a slight decline of 110 basis points year-over-year but a 60 basis points improvement quarter-over-quarter.

Revenue and Growth

The revenue for Q2 FY2027 was ₹20,371 million, which is ₹3,578 million higher than the same period last year. This growth is complemented by a quarter-over-quarter increase of ₹1,575 million, representing an 8.4% rise. The company also experienced a 0.6% decrease in private label revenue compared to Q2 FY26.

Store Expansion and Profitability

MEDPLUS added 166 new stores in Q2 FY2027, bringing the total store count to 5,642. Of these, 101 were net additions beyond Tier-One cities. The company’s store-level EBITDA margin improved to 11.7%, and the operating ROCE (Return on Capital Employed) stood at 72.0%.

Financial Performance

The pharmacy operating EBITDA for the quarter was ₹885 million, showing a 4.4% operating EBITDA margin, up by 120 basis points quarter-over-quarter. The company’s consolidated operating EBITDA reached ₹981 million, and the operating cash flow was ₹370 million, resulting in a 37.7% ratio of operating cash flow to operating EBITDA.

As a forward-looking statement, MEDPLUS remains optimistic about its growth trajectory, leveraging its extensive network of 5,642 stores across 13 states and 1 union territory. The company aims to further penetrate existing clusters and develop new ones, capitalize on its omni-channel strategy, and expand its private label offerings to drive higher margins and customer retention.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Medplus Health Services Limited

Medplus Health Services Limited belongs to the Healthcare › Pharmaceutical Retailers sector. Here’s a quick read on where the business and the stock stand today.

Medplus drops 23.6% over three months and trades near its 52-week lows. The PEG of 0.55 signals undervaluation relative to growth. It is a potential re-rating candidate. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. RSI stands at 26, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. The business compounds at 14.7% revenue and 64.0% profit CAGR, with D/E of 0.64. Yet the stock drops 23.6% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Medplus Health Services Limited.

Mankind Pharma Limited (MANKIND) is set to host an Analyst/Investor Meet on October 2026, providing insights into its growth trajectory and strategic initiatives. The company, which has consistently demonstrated robust performance, will focus on its expansion in chronic and specialty divisions, hospital business, and consumer healthcare segments. With a revenue of ₹14,278 Cr in FY26, the company has shown an 18.1% Revenue CAGR from FY21 to FY26, underscoring its market leadership.

Growth Revival and Strategic Initiatives

The meet will highlight Mankind Pharma’s growth revival through its eight pillars of growth, including scaling branded specialty ACTx, expanding its hospital business, and focusing on good-to-great brands. The company has also made significant strides in consumer healthcare, becoming a leader in sexual wellness and expanding into consumer wellness with brands like Gas-O-Fast and Acne Star.

Future Outlook

Looking ahead, Mankind Pharma aims to deepen its penetration in high-barrier specialty brands and geographical expansion of key products in emerging markets. With a focus on high revenue growth and innovative bets, the company is poised to continue its impressive growth trajectory.

As a result of these strategic initiatives, Mankind Pharma is well-positioned to achieve its goal of becoming a global leader in pharmaceuticals.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Mankind Pharma Limited

Mankind Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Mankind falls 8.4% over three months and has not found a floor yet. The PEG reaches 3.22. The stock trades on brand and index weight, not on growth. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gains 1.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 17.7% and profits at 14.3% CAGR, with D/E of 0.58. Meanwhile, the stock dips 8.4% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Mankind Pharma Limited.